AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

Summary

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD7442 administered intramuscularly (IM) or intravenously (IV) in pediatric participants aged ≥ 29 weeks GA to \< 18 years.

Timeline

Start

2022-03-21

Primary completion

2024-04-16

Completion

2024-04-16

Drugs

Indications